TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8295812
Drug: Clarithromycin (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin (7.5 mg/kg twice daily for 7 to 10 days)
Study: 8295812
Drug: Amoxicillin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin (20 mg/kg twice daily for 7 to 10 days)
Study: 29438162
Drug: Serum insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Serum insulin (highest vs. lowest quartile)
Study: 29438162
Drug: Serum glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum glucose and insulin
Study: 26117922
Drug: Cardioxipin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardioxipin (10 mg/kg daily i/v droplet infusion)
Study: 26117922
Drug: Cytoflavin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytoflavin (10 ml in 200 ml 0.9% sodium chloride solution daily i/v droplet infusion for 10 days)
Study: 26117922
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no treatment with cytoflavin and cardioxipin)
Study: 14672354
Drug: Calcitonin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcitonin treatment (not specified dosage or duration)
Study: 14672354
Drug: No calcitonin
Approvals — FDA: no, EMA: no, PMDA: no
Description: No calcitonin treatment (control group)
Study: 10852316
Drug: Perioperative NSAIDs
Normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Perioperative NSAIDs (medium-to-high-dose regimens)
Study: 6329769
Drug: Oxyphenonium bromide
Normalized name: oxyphenonium bromide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxyphenonium bromide 3 X 10 mg
Study: 6329769
Drug: Terbutaline 3
Normalized name: terbutaline 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutaline 3 X 5 mg
Study: 6329769
Drug: Theophylline 2
Normalized name: theophylline 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline 2 X 300 mg
Study: 31545671
Drug: 3% prilocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3% prilocaine with 0.03 IU/mL felypressin (P + FP)
Study: 31545671
Drug: 2% lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% lidocaine with 1:80,000 adrenaline (L + AD)
Study: 29723393
Drug: Bortezomib added
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bortezomib added to rituximab, high‐dose methotrexate, and high‐dose cytarabine (BzR‐MA)
Study: 26213242
Drug: Cognitive Orientation
Normalized name: Oriental melon
DrugBank: Muskmelon (DB15611)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Orientation to Daily Occupational Performance (CO‐OP) intervention for 10 weeks
Study: 24658945
Drug: High-intensity focused
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-intensity focused ultrasound combined with sonographically guided intratumoral ethanol injection (group H + A)
Study: 24658945
Drug: High-intensity focused
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-intensity focused ultrasound treatment (group H)
Study: 23100167
Drug: Fixed-dose combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose combination (FDC) tablet of mitiglinide and metformin (10 mg/500 mg)
Study: 23100167
Drug: Individual formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual formulations of mitiglinide and metformin
Study: 23100167
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (FDC and individual formulations)
Study: 18846346
Drug: 0.4% carbomer
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4% carbomer gel
Study: 8839230
Drug: ITF 296
Approvals — FDA: no, EMA: no, PMDA: no
Description: ITF 296 (10, 20, 40, 80 micrograms/kg) by 1-min i.v. injection
Study: 2202551
Drug: Choline magnesium
Normalized name: Choline Magnesium Trisalicylate
DrugBank: Choline (DB00122)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Choline magnesium trisalicylate (3.0 g/day)
Study: 2202551
Drug: Enteric-coated acetylsalicylic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteric-coated acetylsalicylic acid (3.0 g/day)
Study: 28338566
Drug: Midazolam (0.06
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.06 mg/kg)
Study: 21904779
Drug: Fentanyl (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl (1 μg/kg)
Study: 25834684
Drug: Traditional oral
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional oral examination format (n=17)
Study: 24166470
Drug: Elective stenosis
Normalized name: hetastarch
DrugBank: Hydroxyethyl Starch (DB09106)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elective stenosis repair (treatment group)
Study: 21480257
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment and adjuvant radiotherapy
Study: 15579215
Drug: Nicotine administered
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine administered by patch
Study: 11684377
Drug: Chlormadinone acetate
Normalized name: Chlormadinone acetate
DrugBank: Chlormadinone acetate (DB15903)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlormadinone acetate (CA) 10 mg/day
Study: 11836042
Drug: Micronized progesterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronized progesterone (MP) 200 mg/day
Study: 9888411
Drug: Oral glutamine
Normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral glutamine (7 g three times per day)
Study: 9888411
Drug: Placebo (7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (7 g glycine three times per day)
Study: 21585330
Drug: 10mg of
Normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10mg of intravenous metoclopramide
Study: 21585330
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g of intravenous paracetamol
Study: 11098022
Drug: Intracytoplasmic sperm
Normalized name: herring sperm DNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracytoplasmic sperm injection (ICSI) with frozen-thawed epididymal spermatozoa
Study: 31475367
Drug: Sildenafil (0.42-2.09
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil (0.42-2.09 mg/kg enterally) in cohort 1
Study: 31475367
Drug: Sildenafil (0.125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil (0.125 or 0.25 mg/kg IV) in cohort 2
Study: 31475367
Drug: IV doses
Normalized name: Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV doses of 0.125, 0.5 and 1 mg/kg every 8 hours (in absence of fluconazole)
Study: 24708672
Drug: Practice team-supported
Approvals — FDA: no, EMA: no, PMDA: no
Description: Practice team-supported self-managed exposure programme with cognitive behaviour therapy-oriented psychoeducation and instructions in four manual-based appointments, plus ten protocol-based telephone contacts for symptom monitoring.
Study: 20511029
Drug: Sequential Compression
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential Compression Device (SCD)
Study: 10227007
Drug: Oral conjugated
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral conjugated equine estrogens (CEE) for 21 days
Study: 10227007
Drug: Oral CEE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral CEE for 21 days followed by 5 mg/day of medrogestone for 7 days
Study: 1650303
Drug: Experimental dentifrice
Normalized name: stannous fluoride
DrugBank: Stannous fluoride (DB11092)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Experimental dentifrice formulations (specific formulations not detailed)
Study: 29440218
Drug: Ramipril (active
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramipril (active treatment group)
Study: 27558421
Drug: Oral Preexposure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Preexposure Prophylaxis (PrEP) with tenofovir
Study: 11772951
Drug: 3.8-4.0 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.8-4.0 g plant stanol esters daily for 8 weeks
Study: 10680989
Drug: DT‐IPV (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: DT‐IPV (50 Lf, 12.5 Lf, 40, 8, 32 DU) at 5, 6 and 15 months of age plus whole‐cell pertussis vaccine (> or = 4 IU) at 5 and 9 weeks and at 10 months of age, n = 84
Study: 2257857
Drug: Cicletanine 100
Normalized name: cicletanine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cicletanine 100 mg
Study: 2344503
Drug: Bendrofluazide 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bendrofluazide 5 mg
Study: 7428646
Drug: Fendiline (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fendiline (3 X 50 mg)
Study: 7428646
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate (ISDN) (2 X 20 mg plus 1 placebo tablet)
Study: 28254636
Drug: MIRT (multidisciplinary
Approvals — FDA: no, EMA: no, PMDA: no
Description: MIRT (multidisciplinary intensive rehabilitation treatment)
Study: 28254636
Drug: MIRT-AT (MIRT
Approvals — FDA: no, EMA: no, PMDA: no
Description: MIRT-AT (MIRT plus aquatic therapy)
Study: 26340977
Drug: Antiplatelet drugs
Normalized name: simethicone
DrugBank: Simethicone (DB09512)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiplatelet drugs or no antithrombotic treatment (control group)
Study: 11806295
Drug: Trimetazidine (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimetazidine (80 mg/kg, group 1)
Study: 11117655
Drug: Ibuprofen liquigel
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen liquigel 200 mg
Study: 11117655
Drug: Ibuprofen liquigel
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen liquigel 400 mg
Study: 8623998
Drug: Edrophonium 1
Normalized name: edrophonium 10 mg/mL injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edrophonium 1 mg.kg‐1
Study: 8955970
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no anticholinesterase drug)
Study: 2821808
Drug: Sucralfate (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucralfate (1 g four times a day)
Study: 1561531
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy of sucralfate (3 times a day) and ranitidine (300 mg after dinnertime)
Study: 29704513
Drug: Regorafenib 160
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Regorafenib 160 mg/day
Study: 27822881
Drug: Sofosbuvir-based treatment
Normalized name: Sofosbuvir
DrugBank: Sofosbuvir (DB08934)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sofosbuvir-based treatment (sofosbuvir and ribavirin with or without pegylated interferon-α)
Study: 23139624
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation of bisoprolol fumarate 5 mg
Study: 17921387
Drug: DHA (88
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA (88 mg/d) and EPA (22 mg/d)
Study: 12382292
Drug: Combined spa
Normalized name: Broda Acne Spa
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined spa therapy and exercise therapy (Group 1)
Study: 12382292
Drug: Combined spa
Normalized name: Broda Acne Spa
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined spa therapy and exercise therapy (Group 2)
Study: 12382292
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (usual activities and standard treatment)
Study: 10450748
Drug: Filgrastim (G-CSF)
Normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Filgrastim (G-CSF) 5 microg/kg/day subcutaneously during and after chemotherapy
Study: 10450748
Drug: Filgrastim (G-CSF)
Normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Filgrastim (G-CSF)
Study: 31082790
Drug: Low-calorie diet
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-calorie diet plus 40 g/d of oat bran
Study: 28689306
Drug: Spine-strengthening exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spine-strengthening exercise and posture training (1 hour, three times weekly for 6 months)
Study: 23511339
Drug: Valsartan 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan 0.25 mg/kg per day
Study: 23511339
Drug: Valsartan 1
Normalized name: valsartan 16 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan 1 mg/kg per day
Study: 23511339
Drug: Valsartan 4
Normalized name: valsartan 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan 4 mg/kg per day
Study: 17311892
Drug: Constant intravenous
Normalized name: constant albicans extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Constant intravenous ghrelin infusion at 5 pmol.kg body wt(‐1).min(‐1) for 180 min
Study: 15502049
Drug: 2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg/kg tramadol
Study: 11208825
Drug: LHRH agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: LHRH agonist plus tamoxifen
Study: 11208825
Drug: LHRH agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: LHRH agonist alone
Study: 9389419
Drug: Pramlintide 60
Normalized name: PRAMLINTIDE 600MCG/ML SOLN INJ 5ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pramlintide 60 microg twice per day
Study: 18478022
Drug: Citalopram infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram infusion (10 mg)
Study: 9299654
Drug: Cetirizine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetirizine (5 mg)
Study: 9389015
Drug: Vit-C (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vit-C (0.1 g)
Study: 1533588
Drug: fosinopril 20
Normalized name: fosinopril 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: fosinopril 20 mg daily
Study: 3907991
Drug: Sustained-release tablet
Normalized name: Oratuss 12 Sustained-Release Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release tablet of ketoprofen (200 mg once daily)
Study: 3907991
Drug: Normal ketoprofen
Normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Normal ketoprofen capsules (2 X 50 mg twice daily)
Study: 3907991
Drug: Sustained-release tablet
Normalized name: Oratuss 12 Sustained-Release Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release tablet of ketoprofen
Study: 3907991
Drug: Normal ketoprofen
Normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Normal ketoprofen capsules
Study: 24802413
Drug: Aromatase inhibitor
Normalized name: Aromatase inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aromatase inhibitor therapy
Study: 18441389
Drug: Insulin stimulation
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin stimulation for 3 hours
Study: 16749289
Drug: Aggressive strategy
Normalized name: ZO SKIN HEALTH Aggressive Anti-Aging Program KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aggressive strategy based on early coronary angiography and subsequent revascularization; specific dosage and duration not available.
Study: 16749289
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (beta-blockers, aspirin, statins); specific dosage and duration not available.
Study: 10958124
Drug: Placebo analgesic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo analgesic injection (saline IM injection resembling ketorolac 60 mg)
Study: 10958124
Drug: Placebo oral
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral analgesia (inactive starch tablet resembling ibuprofen 800 mg)
Study: 9065610
Drug: Tamoxifen 20
Normalized name: tamoxifen 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen 20 mg po daily
Study: 8349838
Drug: 1% w/w
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% w/w flurbiprofen toothpaste, used 2 x daily for 12 months
Study: 3555035
Drug: 750 mg
Normalized name: bran 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 mg of oral ciprofloxacin every 12 hours for two weeks
Study: 3555035
Drug: 1,000 mg
Normalized name: bran 1,000 mg ORAL WAFER
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,000 mg of oral ciprofloxacin every 12 hours for two weeks
Study: 10152782
Drug: Ciprofloxacin therapy
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciprofloxacin therapy
Study: 22056152
Drug: Androgen deprivation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Androgen deprivation therapy (ADT) only
Study: 31899529
Drug: Virtual education
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virtual education via handheld tablet with self-assessment questions, narrated video demonstration, and iterative rounds as needed.
Study: 20206078
Drug: Nifedipine CR
Normalized name: nifedipine Extended Release Oral Tablet [Afeditab CR]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine CR 40 mg (NR)
Study: 20206078
Drug: Benidipine 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benidipine 4 mg (BD)
Study: 16812979
Drug: Dual renin-angiotensin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual renin-angiotensin system blockade (Valsartan added to standard therapy including ACE inhibitor and beta blocker)
Study: 16812979
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (ACE inhibitor and beta blocker)
Study: 11730274
Drug: Dopamine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine infusion (2.5 microg/kg/min)
Study: 7959238
Drug: 0.5 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 g/day olsalazine
Study: 7959238
Drug: 1.0 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 g/day olsalazine
Study: 7959238
Drug: 2.0 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0 g/day olsalazine
Study: 7959238
Drug: 2.0 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0 g/day olsalazine in patients with proctitis
Study: 7959238
Drug: 2.0 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0 g/day olsalazine in patients in remission for less than 12 months
Study: 22071061
Drug: PCEA-only (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCEA-only (10 mL, at 20 minutes)
Study: 22071061
Drug: CEI-only (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEI-only (10 mL/h)
Study: 22071061
Drug: CEI +
Normalized name: Ceiba pentandra fiber
DrugBank: Ceiba pentandra fiber (DB10411)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEI + PCEA (CEI 10 mL/h plus PCEA 10 mL, at 20 minutes)
Study: 12734084
Drug: Perioperative chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perioperative chemotherapy (POC) with 14 mg/m(2) mitoxantrone infusion at the end of tumor excision
Study: 12734084
Drug: Standard adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard adjuvant treatment (including tamoxifen for postmenopausal women)
Study: 8995348
Drug: Daflon 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daflon 500 mg (Dios), two tablets/day for two months, in addition to compression therapy
Study: 8995348
Drug: Daflon 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daflon 500 mg (Dios)
Study: 8388353
Drug: Subcutaneous injection
Normalized name: EPINEPHRINE 0.3 mg SUBCUTANEOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection of Fraxiparin daily (group I)
Study: 26232172
Drug: Intravenous magnesium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous magnesium (40 mg/kg every 8 hours for up to 6 doses)
Study: 26232172
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline placebo (every 8 hours for up to 6 doses)
Study: 21353271
Drug: Triple combination
Normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple combination therapy of albendazole, ivermectin, and praziquantel
Study: 18348383
Drug: Active drug
Normalized name: Capillary active drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active drug (patch with extract of glycyrrhiza root)
Study: 21429413
Drug: Bi-level positive
Normalized name: bis-ethoxydiglycol succinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bi-level positive airway pressure (BIPAP) treatment
Study: 9839760
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg donepezil for 28 days
Study: 9839760
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg donepezil for 21 days after 7 days of 5 mg donepezil
Study: 9839760
Drug: Both dosage
Normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both dosage regimens (5 mg and 10 mg donepezil)
Study: 8076659
Drug: ACE inhibitors
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitors (delayed initiation beyond 24 hours and long-term maintenance treatment)
Study: 8076659
Drug: Immediate aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Immediate aspirin and thrombolytic therapy
Study: 29987456
Drug: Prednisolone and
Normalized name: prednisolone and mydriatics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone and mizoribine with warfarin and dipyridamole (group 1)
Study: 29987456
Drug: Prednisolone and
Normalized name: prednisolone and mydriatics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone and mizoribine without warfarin and dipyridamole (group 2)
Study: 28325124
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no obstetric gel)
Study: 28325124
Drug: Obstetric gel
Normalized name: chlorhexidine gluconate Topical Cream [Hibitane Obstetric]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Obstetric gel (among nulliparous women)
Study: 28325124
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no obstetric gel, among nulliparous women)
Study: 23701411
Drug: Levofloxacin 750
Normalized name: levofloxacin 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin 750 mg single-dose (150 mL)
Study: 23701411
Drug: Levofloxacin 750
Normalized name: levofloxacin 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin 750 mg multiple-dose (150 mL once daily for 7 days)
Study: 23701411
Drug: Levofloxacin 750
Normalized name: levofloxacin 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin 750 mg regimen
Study: 19016090
Drug: Cognitive behaviour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behaviour therapy for BN (duration not specified)
Study: 14577344
Drug: DOT (Directly
Approvals — FDA: no, EMA: no, PMDA: no
Description: DOT (Directly Observed Therapy) during admission